Managing the High Cost of a First-Line Lung Cancer Drug

National Harbor, Md.—Ever since the U.S. government approved a lung cancer drug as a first-line therapy, patient use has skyrocketed—and because the drug is significantly more expensive than its competitors, so have drug costs.